Palatin Technologies(PTN)

Focus: Palatin Technologies is a public biotech company focused on small-molecule therapeutics across multiple therapeutic areas including ophthalmology, cardiovascular, respiratory, nephrology, and immunology. The company operates at a pre-revenue to minimal-revenue stage with a public listing (PTN) but negligible commercial traction.

Ophthalmology Cardiovascular Respiratory Nephrology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Palatin Technologies

AI assessmentNot Hiring

No open roles listed right now. Follow Palatin Technologies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$4M

Pipeline & Clinical Trials

Bremelanotide

Sexual Arousal Disorder

PHASE_2

Clinical Trials (1)

NCT00425256Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Phase 2

Help build intelligence for Palatin Technologies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Multi-indication pipeline with 12 active programs including Phase 3 candidates (Bremelanotide for HSDD, ophthalmic solutions for dry eye) offering exposure to multiple therapeutic areas
Small-molecule focus provides technical breadth across modalities and indication areas, valuable for chemists and medicinal scientists
Public company structure enables stock-based compensation and access to capital markets, though with execution-dependent upside

Watch Out For

Severe cash burn: $29.7M net loss on only $4M revenue in FY2025, with cash position declining from $10M to $3M year-over-year—runway concerns are real
Zero active job openings and minimal hiring signal; the company appears to be in preservation mode, not growth mode
Unproven commercial capability: no marketed drugs, minimal revenue, and 5 publications suggest limited clinical validation and market presence

Generated by Claude from Palatin Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

PL-3994

Asthma

PHASE_2

Clinical Trials (1)

NCT01304628Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

Phase 2

Bremelanotide

Kidney Disease

PHASE_2

Clinical Trials (1)

NCT05709444A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Phase 2

PL8177 Placebo

Ulcerative Colitis

PHASE_2

Clinical Trials (1)

NCT05466890Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

Phase 2

PL3994

Hypertension

PHASE_2

Clinical Trials (1)

NCT00686803Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension

Phase 2

bremelanotide

Female Sexual Arousal Disorder

PHASE_2

Clinical Trials (1)

NCT01382719Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

Phase 2

PL-3994 Aqueous Intravenous Solution Dose Ascention

Heart Failure With Preserved Ejection Fraction

PHASE_2

Clinical Trials (1)

NCT04318145Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

Phase 2

bremelanotide

Obesity

PHASE_2

Clinical Trials (1)

NCT06565611A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

Phase 2

PL9643 Ophthalmic Solution

Dry Eye Disease

PHASE_2

Clinical Trials (1)

NCT04268069Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Phase 2

Bremelanotide

Hypoactive Sexual Desire Disorder

PHASE_3

Clinical Trials (1)

NCT023389602. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Phase 3

Bremelanotide

Hypoactive Sexual Desire Disorder

PHASE_3

Clinical Trials (1)

NCT023330711. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Phase 3

Vehicle Ophthalmic Solution

Dry Eye

PHASE_3

Clinical Trials (1)

NCT05201170A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1997

Portfolio: 12 clinical trials

Top TAs: Cardiovascular, Ophthalmology, Immunology

Publications: 25 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

2 pipeline

2 pipeline

1 pipeline

1 pipeline

1 pipeline

Financials (FY2025)

Revenue

$4M7%

R&D Spend

$22M(499%)1%

Net Income

-$30M

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

2023

PMID:37677000

A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans.

Frontiers in immunology

2023

PMID:36891301

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo